Dare Bioscience (DARE) Stock Price, News & Analysis

Company Overview

Daré Bioscience, Inc., a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older. It is developing Ovaprene, a hormone-free, monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia on demand for the treatment of female sexual arousal disorder; DARE-HRT1 to treat moderate to-severe vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of moderate-to-severe dyspareunia or pain during sexual intercourse; and DARE-CIN to treat cervical intraepithelial neoplasia and other human papillomavirus related pathologies. The company is also developing DARE-PDM1 for the treatment of primary dysmenorrhea; DARE-204 and DARE-214, an injectable formulations contraception of etonogestrel designed to provide contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth. In addition, it is developing DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design that controlled contraceptive option; DARE-LBT, a novel hydrogel formulation for vaginal delivery of live biotherapeutics to support vaginal health; DARE-GML, a multi-target antimicrobial agent; DARE-RH1, a novel approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; and DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein. Daré Bioscience, Inc. is headquartered in San Diego, California.

Key Stats

• Today's Range: $1.83 to $2.05
• 50-Day Range: $1.92 to $3.26
• 52-Week Range: $1.83 to $9.19
• Volume: 405,635 shs
• Average Volume: 4.65 million shs
• Market Capitalization: $17.34 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $12.00
• Consensus Rating: Moderate Buy

Dare Bioscience Stock Analysis - MarketRank™

Dare Bioscience scored higher than 22% of companies evaluated by MarketBeat, and ranked 817th out of 925 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Dare Bioscience has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Dare Bioscience has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Dare Bioscience are expected to decrease in the coming year, from ($0.49) to ($1.90) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Dare Bioscience is -11.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Dare Bioscience is -11.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

12.74% of the float of Dare Bioscience has been sold short.

Short Interest Ratio / Days to Cover

Dare Bioscience has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Dare Bioscience has recently increased by 2,276.87%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Dare Bioscience does not currently pay a dividend.

Dividend Growth

Dare Bioscience does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

12.74% of the float of Dare Bioscience has been sold short.

Short Interest Ratio / Days to Cover

Dare Bioscience has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Dare Bioscience has recently increased by 2,276.87%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 1.1 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Dare Bioscience this week, compared to 1 article on an average week.

Search Interest

13 people have searched for DARE on MarketBeat in the last 30 days.

MarketBeat Follows

2 people have added Dare Bioscience to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Dare Bioscience insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 4.00% of the stock of Dare Bioscience is held by insiders.

Percentage Held by Institutions

Only 6.70% of the stock of Dare Bioscience is held by institutions.

DARE Stock Analysis - Frequently Asked Questions

How have DARE shares performed this year?

Dare Bioscience's stock was trading at $3.12 at the beginning of 2025. Since then, DARE stock has decreased by 38.5% and is now trading at $1.92.

How were Dare Bioscience's earnings last quarter?

Dare Bioscience, Inc. (NASDAQ:DARE) issued its earnings results on Tuesday, May, 13th. The biotechnology company reported ($0.50) EPS for the quarter, topping the consensus estimate of ($0.63) by $0.13. The biotechnology company earned $0.03 million during the quarter, compared to analyst estimates of $0.60 million.
Read the conference call transcript.

When did Dare Bioscience's stock split?

Dare Bioscience's stock reverse split on the morning of Monday, July 1st 2024.The 1-12 reverse split was announced on Monday, July 1st 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, July 1st 2024. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

Who are Dare Bioscience's major shareholders?

Dare Bioscience's top institutional shareholders include AMH Equity Ltd (2.14%).
View institutional ownership trends.

How do I buy shares of Dare Bioscience?

Shares of DARE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Dare Bioscience own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Dare Bioscience investors own include FuelCell Energy (FCEL), Tonix Pharmaceuticals (TNXP), Tesla (TSLA), Vaxart (VXRT), Inovio Pharmaceuticals (INO), VBI Vaccines (VBIV) and Advanced Micro Devices (AMD).

Company Calendar

• Last Earnings: 5/13/2025
• Today: 8/09/2025
• Next Earnings (Estimated): 8/14/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:DARE
• CIK: 1401914
• Web: www.darebioscience.com
• Phone: (858) 926-7655
• Fax: 617-494-1544
• Employees: 30
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Dare Bioscience: $12.00
• High Price Target: $12.00
• Low Price Target: $12.00
• Potential Upside/Downside: +525.0%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.17)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$4.05 million
• Net Margins: N/A
• Pretax Margin: -6,708.00%
• Return on Equity: N/A
• Return on Assets: -8.14%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.56
• Quick Ratio: 0.56

Sales & Book Value

• Annual Sales: $10 thousand
• Price / Sales: 1,733.76
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.69) per share
• Price / Book: -2.78

Miscellaneous

• Outstanding Shares: 9,030,000
• Free Float: 8,669,000
• Market Cap: $17.34 million
• Optionable: Not Optionable
• Beta: 1.11